Back to all Current clinical trials
Back to all Current clinical trials
ABTECT-1: A potential new treatment for UC
The ABTECT-1 Study is being done to learn more about an investigational medication, called Obefazimod or ‘ABX464’, and its effect in people with ulcerative colitis (UC). UC causes inflammation in the lining of the colon (large
intestine). The main symptoms of UC are pain and recurring diarrhoea, which may contain blood and/or mucus.
This study aims to check:
- if 2 different doses of the study medication work in controlling the symptoms of UC
- how safe the investigational medication is.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
-
ERM Project ID
100622
Trial contact details
-
Contact person
Sharyn Grossman
-
Phone
0400 757 347
What you need to know
Who can take part?
To participate, you must:
- Be 18-75 years of age
- Have UC diagnosis confirmed by endoscopy & histology
- Have had previous treatment for UC (confirm requirements with study team)
- Have test results within expected ranges
- Not have an additional condition that may impact your UC treatment
- Not have failed 5-ASA only therapy
- Have planned surgery
- Not be taking probiotics
What is involved for me?
- Take one tablet, daily
- Colonoscopy with biopsy
- Blood tests
- Daily diary completion
- Vital Signs
- ECG
- Questionnaires
- Eye exam
- Stool tests
- Optional Cardiac testing
